Abstract: The present disclosure relates to an apparatus for an eye contact video call capable of a realistic call in eye contact with the other party. A transparent display is formed at a central part of the opaque display and a camera is formed at a rear side thereof, thereby allowing a realistic call in eye contact with the other party and at the same time, the readability to be improved even in cases of a usual display use (mode). Further, the manufacturing cost of a terminal may be reduced and an interference of an output video of a transparent display that exists in the camera photograph video may also be effectively eliminated.

Abstract: The present invention provides moieties that bind to an Ig-like domain, e.g., D4 or D5, of a human receptor tyrosine kinase, e.g., the human Kit RTK or the PDGFR RTK, or the D7 domain of a type V receptor tyrosine kinase wherein the moieties lock the ectodomain of the receptor tyrosine kinase in an inactive state thereby antagonizing the activity of the receptor tyrosine kinase.

Abstract: Pulse width modulation is provided for controlling a resonant power converter, particularly for dimming of light emitting diode arrays without loss of efficiency. Dynamic oscillation due to the beginning of a pulse width modulated pulse burst is limited by shortening of the first and/or last pulse of a pulse bust such that the first pulse of a subsequent pulse burst close to or to connect with a full load steady-state voltage/current trajectory of the power converter. Pulse shortening made be made substantially exact to virtually eliminate dynamic oscillation but substantial reduction in dynamic oscillation is provided if inexact or even performed randomly.

Abstract: The present invention is directed to a pharmaceuticalm composition comprising a peptide comprising at least a portion corresponding to the C-terminus of FGF23 and an additive selected from the group consisting of vitamin D and a vitamin D receptor agonist.

Abstract: Highly potent dendritic cells are generated in vivo or ex vivo by exposing precursor cells to an effective dose of IL-32.

Abstract: A method, apparatus and medium are provided for detecting anomalous payloads transmitted through a network. The system receives payloads within the network and determines a length for data contained in each payload. A statistical distribution is generated for data contained in each payload received within the network, and compared to a selected model distribution representative of normal payloads transmitted through the network. The model payload can be selected such that it has a predetermined length range that encompasses the length for data contained in the received payload. Anomalous payloads are then identified based on differences detected between the statistical distribution of received payloads and the model distribution. The system can also provide for automatic training and incremental updating of models.

Abstract: A field emission display includes a panel and a control unit. The panel has a number of pixel units. Each of the pixel units has at least one fluorescent layer. The control unit which electrically connects to the pixel units receives an objective image. The control unit further selects a part of the pixel units corresponding to the objective image, divides the part of the pixel units into a number of pixel unit groups, and scans the pixel unit groups to make the plurality of pixel unit groups sequentially work such that the panel displays the objective image.

Abstract: This application describes an antibody that specifically binds to a synthetic oligomer (e.g., an oligonucleotide or oligopeptide) having a organic protecting group covalently bound thereto, which antibody does not bind to that synthetic oligomer when the organic protecting group is not covalently bound thereto. Methods of making and using such antibodies are also disclosed, along with cells for making such antibodies and articles carrying immobilized oligomers that can be used in assay procedures with such antibodies.

Abstract: A method for forming a fluorinated compound includes a step of forming a sulfonate ester of a polyethylene glycol. The sulfonate ester is then reacted with a fluorinated diol in the presence of a base such that the polyethylene glycol is attached to one of the hydroxyl groups in the fluorinated diol. The other hydroxyl group in the fluorinated diol is reacted is converted into a leaving group and reacted with an number of nucleophiles. Complexes of the fluorinated compounds that as useful in Magnetic Resonance Imaging are also provided.

Abstract: A straightforward single step method for the preparation and/or production of substituted quinazolines is disclosed, wherein said quinazolines preferably contain one substituent at position 4, and may contain other functional groups at various positions, such as 5, 6, 7, and/or 8 of quinazolines. In addition, the extension of this new method leads to the formation of different type of heterocyclic aromatic compounds, that include but are not limited to perimidines, anthrapyrimidin-7-ones (also known as anthrapyrimidinones), anthra[1,9:5,10]dipyrimidines (also known as quinazoline[5,4-ef]perimidines) and benzo[e]-pyrimido[4,5,6-gh]pyrimidines.

Abstract: Graft copolymer polyelectrolyte complexes are disclosed for the efficient delivery of anionic, cationic or polyelectrolyte therapeutic agents into biological cells, and for maintaining the biological activity of these molecules while in serum and other aqueous environments are provided. Such complexes comprise (1) an anionic graft copolymer containing an anionic polymer backbone, with pendent carboxylic acid groups and pendant chains containing amphipathic or hydrophilic polymers covalently bonded to a portion of the pendant carboxylic acid groups, (2) one or more anionic, cationic or polyelectrolyte therapeutic agents, and (3) optionally a liposome optionally containing an additional therapeutic agent. Also disclosed are functional nanoparticles containing the complexes.

Abstract: The present invention provides compounds that function as modulators of mitochondrial aldehyde dehydrogenase-2 (ALDH2) activity; and pharmaceutical compositions comprising the compounds. The present invention provides therapeutic methods involving administering a subject compound, or a subject pharmaceutical composition. The present invention further provides assays for identifying agonists of ALDH2.

Abstract: There are provided a battery electrode wherein an active material layer is formed on a collector surface, and the layer contains an active material and a block copolymer having a vinyl alcohol polymer block; and a lithium ion secondary battery having a laminate structure in which a pair of electrodes having an active material layer are disposed in such a manner that the active material layers face each other via a separator, and an electrolyte composition containing a lithium-containing electrolyte salt fills the gaps between the pair of electrodes and the separator, wherein at least one of the pair of electrodes is the above battery electrode. Thus, there can be provided a lithium ion secondary battery which can be easily produced and be less polarized, exhibiting excellent charge/discharge properties and cycle characteristics.

Abstract: Methods for controlling light transmission through a medium by transmitting light from a single spatial portion of an input optical field through the medium creating an output optical field, superposing the output optical field with a reference optical field creating an optical interference field, detecting an intensity of a spatial portion of a polarization component of the optical interference field and using the detected intensity to determine a value of an optical field amplitude and of an optical field phase for each of a plurality of spatial portions of the input optical field and for each of first and second orthogonal input polarization states of transmitted light entering the medium. The method may be used in the control of the transmission of light 1) through a medium, which is randomizing in amplitude, phase and/or polarization or 2) through a multi-mode fiber or for beam shaping, optical trapping and/or optical manipulation.

Abstract: The present invention provides a heat-resistant bearing characterized in that it is formed of an Ni3(Si,Ti)-based intermetallic compound alloy, the Ni3(Si,Ti)-based intermetallic compound alloy containing 25 to 500 ppm by weight of B with respect to a weight of an intermetallic compound having a composition of 100% by atom in total consisting of 10.0 to 12.0% by atom of Si, 1.5% by atom or more but less than 7.5% by atom of Ti, more than 2.0% by atom but 8.0% by atom or less of Ta and a balance made up of Ni excepting impurities, the Ni3(Si,Ti)-based intermetallic compound alloy having a microstructure composed of an L12 phase and of one or both of an Ni solid solution phase and a second phase dispersion containing Ni and Ta, or a microstructure composed of an L12 phase.

Abstract: The use of SIRT7 (sirtuin 7) as a marker for diagnosis of liver cancer is described. The disclosure variously relates to a liver cancer diagnostic marker including SIRT7 gene, a liver cancer diagnostic composition, a kit and microarray including the same, and a method of diagnosing liver cancer using the same. Also described is a method for screening a substance capable of treating liver cancer by inhibiting the expression of SIRT7 gene or protein, and a composition for preventing or treating liver cancer, which includes such substance. The disclosure further relates to the use of SIRT7 gene as a cancer diagnostic marker and the anticancer use of inhibition of SIRT7 expression, as well as the use of the specific miRNA to regulate the cell cycle and inhibit tumor growth by the expression of SIRT7 gene.

Abstract: The invention provides articles of manufacture comprising biocompatible nanostructures comprising nanotubes and nanopores for, e.g., organ, tissue and/or cell growth, e.g., for bone, kidney or liver growth, and uses thereof, e.g., for in vitro testing, in vivo implants, including their use in making and using artificial organs, and related therapeutics. The invention provides lock-in nanostructures comprising a plurality of nanopores or nanotubes, wherein the nanopore or nanotube entrance has a smaller diameter or size than the rest (the interior) of the nanopore or nanotube. The invention also provides dual structured biomaterial comprising micro- or macro-pores and nanopores. The invention provides biomaterials having a surface comprising a plurality of enlarged diameter nanopores and/or nanotubes.

Abstract: An in vitro cell assay for detecting an effect a test condition has on one or more cells. The assay comprises providing a binary half-adder system comprising first and second oscillating cells, and detecting an effect a test condition has on the oscillation of said first and/or second cells.

Abstract: A method and apparatus for managing a stack used for a tree traversal (TRV) may include a processing unit that may manage a short stack for a tree TRV, and a storage unit that may store data of the short stack. The processing unit may perform a restart of the tree TRV from an intermediate node of a tree to fill the short stack when the short stack is empty.

Abstract: Bracytherapy devices include a respective tether attached to a proximal end portion of the strands. The tether can be color-coded to match a color associated with the corresponding strand.